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ABSTRACT: Bacteriophages (phages, bacteria-specific viruses)
have biotechnological and therapeutic potential. To apply phages
as pure or heterogeneous mixtures, it is essential to have a robust
mechanism for transport and storage, with different phages having
very different stability profiles across storage conditions. For many
biologics, cryopreservation is employed for long-term storage and
cryoprotectants are essential to mitigate cold-induced damage.
Here, we report that poly(ethylene glycol) can be used to protect
phages from cold damage, functioning at just 10 mg·mL−1 (∼1 wt
%) and outperforms glycerol in many cases, which is a currently
used cryoprotectant. Protection is afforded at both −20 and −80 °C, the two most common temperatures for frozen storage in
laboratory settings. Crucially, the concentration of the polymer required leads to frozen solutions at −20 °C, unlike 50% glycerol
(which results in liquid solutions). Post-thaw recoveries close to 100% plaque-forming units were achieved even after 2 weeks of
storage with this method and kill assays against their bacterial host confirmed the lytic function of the phages. Initial experiments
with other hydrophilic polymers also showed cryoprotection, but at this stage, the exact mechanism of this protection cannot be
concluded but does show that water-soluble polymers offer an alternative tool for phage storage. Ice recrystallization inhibiting
polymers (poly(vinyl alcohol)) were found to provide no additional protection, in contrast to their ability to protect proteins and
microorganisms which are damaged by recrystallization. PEG’s low cost, solubility, well-established low toxicity/immunogenicity,
and that it is fit for human consumption at the concentrations used make it ideal to help translate new approaches for phage therapy.
■ INTRODUCTION
The use of biologic therapies (e.g., cells, proteins, viruses,
vaccines) is rapidly growing, but there remain challenges to
delivering them intact and functional to a patient.1−5
Bacteriophages (literally “bacteria eater”) or phages are viruses
that specifically target and infect bacteria and are the most
abundant organisms on earth.6 Competition between these
viral predators and their bacterial hosts plays an important role
in the evolutionary adaptations and diversification seen in
many bacteria today.7,8 Generally, phages can be divided into
virulent and temperate phages, the former carrying out a lytic
replication cycle, where the phage uses the bacterial host to
replicate by seizing the host’s molecular machinery and then
escaping the cell to find a fresh host, the latter integrating into
and then remaining dormant in the host genome as a
“prophage” and replicating with the host genome in a lysogenic
cycle.9 Phages are ubiquitous, from the depth of the oceans to
hospital effluents.10 It is also becoming increasingly clear that
phages play a role in the gut microbiome of the human
body.11,12 In aquacultures (the farming of seafood), lytic
phages have been used to alleviate pathogenic bacteria of a
range of fish and shellfish.13 Phages have been approved for use
as a food additive in meat products to protect consumers
against Listeria monocytogenes by the Food and Drug Agency
(FDA).14 Another use of lytic phages is to treat bacterial
infections inside the human body (phage therapy).10 One of
the positive attributes of phage therapy is that they can largely
be applied without disruptions to the gut microbiota.15 The
vast abundance of the phage in nature16 also means that there
is almost an endless pipeline and so phages can be applied as
“cocktails”, thereby reducing the chances of resistance
developing to individual treatment.17−19
Phase II clinical trials on the bacteriophage are being
undertaken, including against multidrug-resistant bacteria. For
example, clinical improvement or full recovery was reported in
up to 40% of 157 patients at the European Phage Therapy Unit
(PTU) between 2008 and 2010;20 venous leg ulcers, using
Intralytix phage cocktail WPP-201 targeting Escherichia coli,
Staphylococcus aureus, and Pseudomonas aeruginosa reported no
adverse effects;21 T4 coliphage cocktail and Microgen
ColiProteus phage cocktail targeting E. coli, which reported
no adverse effects, but the trial was terminated due to a lack of
therapeutic effects.22 While the above are promising, no phage
therapy has reached Phase III trials (to the best of our
knowledge) nor is used as mainstream treatments in the USA
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or EU.23 This can partially be ascribed to a discrepancy
between in vitro and in vivo data and a lack of understanding of
the complex relationship between phages, bacteria, and human
host24−26 but is also due to regulatory and commercial
production and translation barriers. For example, there have
been safety concerns relating to bacteriophage production for
commercial use,27 with fears that the phage could transfer
virulence factors from the bacteriophage’s host bacterium to
pathogens in the patient.28 Problems with the commercial
scale-up of bacteriophage purification were highlighted in the
PhagoBurn phase I/II clinical trials, where work was halted
multiple times, because of technological difficulties in
bacteriophage production29 and regulatory barriers.
One important factor to consider when producing a
commercially viable treatment is its storage options and
stability over time (shelf-life). The biologic storage challenge
has been highlighted during the development of vaccines for
COVID-19, with several requiring sub −20 °C temperatures
and hence appropriate cold-chain infrastructure to enable
global roll-out.3 One reliable method for phage cryopreserva-
tion is storage inside the bacterial host.30 From a phage therapy
point of view, however, the use of the infective phages requires
the removal of the hosts, e.g., using chloroform and vigorous
vortexing steps, and this comes with the concern that phage
preparations are not always purified from their host endotoxins
or potentially toxic purification reagents.10,31
Phage storage at ambient temperature is possible, but the
success and longevity of this vary from phage to phage. For
example, Acinetobacter baumannii phage vPhT2 was reported
to have excellent stability in lysogeny broth but not in SM-II (a
standard buffer for phage storage).18 Finding a suitable method
for long-term storage for purified phages or developing
preparations for standardized phage transport, storage, and
use at the bed-side is important for their wider adoption. For
example, many cell-based therapies are stored cryopreserved
and thawed before use.32,33 Predictable cryopreservation
outcomes are essential to control dosage, and in the case of
cocktails, the thawed composition matches the frozen.
The cryopreservation of nucleated cells, bacteria, and
proteins is typically achieved by the addition of (one or
more) cryoprotectants to mitigate cold-induced damage, with
dimethyl sulfoxide (DMSO) and glycerol being the most
widely used cryoprotectants,34−38 but there is a desire to
reduce or remove the volume of these used to increase post-
thaw recovery and to reduce potential toxicity.39−41 Extrem-
ophiles survive in subzero climates by a series of adaptive
mechanisms, which include the production of cryoprotectants,
such as trehalose, glycerol, and osmolytes,42−44 as well as ice
binding proteins (IBPs), which can prevent or promote ice
formation and growth.45 There has been significant interest in
developing synthetic materials to mimic the function of IBPs
and other cryoprotectant molecules, with particular focus on
their application in cryopreservation.46−49 Polyampholytes
have been shown to be potent mammalian cell cryopreserva-
tion enhancers.50−52 Ice recrystallization inhibitors (IRIs) have
also found application, with antifreeze proteins53 being shown
to reduce hemolysis in erythrocyte cryopreservation and since
have been studied in several cryopreservation scenarios.54−56
Bacteria and protein storage have been enhanced by IRIs,57,58
by preventing irreversible aggregation. The exact mechanism of
protection (and damage) when using macromolecular
cryoprotectants is still being studied and there is a need to
compare how these materials can protect different organisms.
Here, we explore the use of synthetic polymers as low-
concentration cryoprotectants for the bacteriophage of
potential medical importance. Polymeric recrystallization
inhibitors were tested but found not to provide additional
protection to the phage during freeze/thaw. In contrast, the
addition of (IRI inactive) poly(ethylene glycol), PEG, was
found to enhance post-thaw recovery, in many cases allowing
full recovery of phage at just 1 wt %, comparable to the positive
control of 50 wt % glycerol (a known cryoprotectant). The
bactericidal effect of the phage was also demonstrated to be
retained post-thaw and initial experiments suggest that a range
of water-soluble polymers could have this function, not just
PEG. These observations show that macromolecular cryopro-
tectants for the phage can be formulated from simple off-the-
shelf polymers and in particular may help develop frozen
formulations for future phage-based therapies.
■ EXPERIMENTAL SECTION
Materials and Methods. Agarose, lysogeny broth (LB), poly-
(ethylene glycol) PEG (Mn 4000), poly(vinyl alcohol) (PVA) (MW
10 000, dialyzed), and poly(vinylpyrrolidone) (PVP) (Mn 40 000)
were purchased from Sigma-Aldrich (Merck). Cesium chloride,
magnesium sulfate heptahydrate, sodium chloride, and PEG (Mn
8000) were purchased from Fisher Scientific. Glycerol was purchased
from Scientific Laboratory Supplies (SLS). Hydroxyethyl starch
(HES) was purchased from Carbosynth. Phosphate-buffered solution
(PBS) (8 g·L−1 NaCl, 0.2 g·L−1 KCl, 1.15 g·L−1 Na2HPO4, 0.2 g·L
−1
KH2PO4) and Tris-HCl (24.2 g·L
−1 Tris, 80 g·L−1 NaCl) were
prepared by media preparation facility in the School of Life Sciences
at the University of Warwick. SM-I buffer (1 M NaCl, 8 mM MgSO4·
7H2O, 22.5 mM Tris-HCl pH 7.5) and SM-II buffer (100 mM NaCl,
8 mM MgSO4·7H2O, 22.5 mM Tris-HCl pH 7.5) was prepared in-
house.
Physical and Analytical Methods. Ice Recrystallization
Inhibition Splat Assay. The ice recrystallization inhibition (IRI)
activity of the PEG and PVA polymers was measured using a modified
splat assay.59 A 10 μL sample of each polymer dissolved in SM buffer
II was dropped 1.4 m onto a chilled glass coverslip placed on an
aluminum plate on dry ice. Upon hitting the chilled coverslip, an ice
wafer was formed instantaneously. The glass coverslip was transferred
to a Linkam THMS600 cryostage and left to anneal at −8 °C under a
N2 atmosphere for 30 min after taking an initial photograph at t = 0.
Photographs (initial and after 30 min of annealing) were collected
using an Olympus CX 41 microscope with a UIS-2 20×/0.45/∞/0-2/
FN22 lens and crossed polarizers (Olympus Ltd., Southend-on-Sea,
U.K.), which was equipped with a Canon DSLR 500D digital camera.
Processing of each image was conducted using the freely available Fiji
(ImageJ) software.60 In summary, the number of crystals in the 20×
magnified images of the wafers were counted. Average values obtained
were compared to the values of the SM-II buffer controls.
Biological Methods. Viral Enrichment: Propagation of K1F-GFP
and T4 Bacteriophages. To propagate the bacteriophage isolates, E.
coli EV36 and E. coli AB1157 hosts for the K1F-GFP and T4 phage,
respectively, were grown overnight in lysogeny broth (LB) (Sigma-
Aldrich: Lennox, 10 g·L−1 tryptone, 5 g·L−1 yeast extract, 5 g·L−1
NaCl) at 37 °C and 130 rpm. E. coli AB1157 was only used for the
propagation of the T4 phage, not as the host for any of the assays
described below. The next morning, 1 mL of the overnight liquid
cultures was used to inoculate 50 mL of fresh LB separately. This
newly inoculated LB was incubated at 37 °C and 130 rpm until an
OD600 (optical density at 600 nm) of 0.3 was reached. At this point,
100 μL of the bacteriophage stock was added to each corresponding
flask and the samples were incubated for a further 4 h. The E. coli
EV36 and AB1157 bacterial debris were pelleted by centrifugation at
3220 xg for 10 min before passing the supernatant through a 0.2 μm
pore-size membrane filter. Two prepared phage stocks in LB were
stored at 4 °C.
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Cesium Chloride Purification of K1F-GFP and T4 Phages. For the
purification of both bacteriophages (K1F and T4), the previously
propagation assay described above was scaled up to 250 mL per
sample by transferring the supernatant. Sodium chloride was added to
each sample to achieve a final concentration of 1 M. After incubation
on ice for 1 h, each phage sample was centrifuged at 3220 xg and the
supernatant was filtered through at 0.2 μm pore-size membrane before
adding PEG-8000 to a final concentration of 10% w/v. Both samples
were left overnight at 4 °C, before centrifugation at 25 000 xg for 1 h.
Phage pellets were resuspended in 6−7 mL of SM buffer I and passed
through a 0.2 μm pore-size membrane, before undergoing
concentration and purification in a CsCl gradient for 20 h at
150 000 xg and 4 °C. Following the centrifugation, the extracted
phage band was first dialyzed in SM buffer I and twice dialyzed in SM
buffer II to remove the CsCl. Purified phage samples were stored at 4
°C.
Cryopreservation. The purified bacteriophage samples were
diluted to a final concentration of 1 × 107 PFU·mL−1 in 500 μL of
phage + additive aliquots. After placing the samples in either −20 or
−80 °C freezers (the cooling rate was not recorded), the vials were
left in the freezer for 13 days. After the cryopreservation, each sample
was thawed to 20 °C on benchtops. For the freeze/thaw cycles,
samples were frozen for 30 min before thawing.
Plaque Assay: Quantification of Bacteriophages. Bacteriophage
titers for both K1F-GFP and T4 phages were determined via a soft
agar plaque assay, using 0.7% agar top lysogeny broth agar (LBA).61 A
100 μL aliquot of the serially diluted cryopreserved phage was
incubated with an equal volume of bacteria host cell lawn (∼1 × 108
CFU·mL−1 (colony-forming units)) at room temperature for 15 min
before the addition of 3 mL of liquid top agar (0.7% agar) and
pouring over a solid 1.5% agar LBA plate. After an overnight (24 h)
incubation at 37 °C, the individually distinct zones of clearance on
plates (plaques) were enumerated and quantified as PFU·mL−1
(plaque-forming units) taking into account the serial dilution from
frozen aliquots. The assays were carried out in triplicate, using
duplicates for each biological repeat (n = 6).
Twenty-Four-Hour E. coli EV36 Growth Curves. Samples were
grown in a FLUOstar Omega microplate reader at 37 °C taking
measurements of the optical density (OD600 or Abs600) every 5 min
over a 24 h period. The final concentration of the 1 × 106 CFU·mL−1
bacteria host was added to each well of a 96-well plate and grown for
4 h at 37 °C with shaking to reach the log phase. During the log
phase, the tested aliquots were added to each corresponding well of
the plate including 1% v/v Chemgene surface disinfectant (a positive
control) and bacteriophages with a final concentration of 1 × 106
PFU·mL−1 with or without the polymer additives. All samples were
grown shaking in lysogeny broth (LB) media in a total volume of 200
μL. Data was obtained using the MARS data analysis software
(Version 5.10). The growth curve was carried out in triplicate, using
technical duplicates for each biological repeat (n = 6).
Bacterial Viability/Bacteria Eradication Assay: Quantifying of E.
coli Colonies at Various Time Points. At three time points of interest,
7 h (the first dip in the growth curve), 10 h (slowing of the E. coli
repopulation rate), and 24 h (end of OD readings), the CFU·mL−1 of
the E. coli was determined using a modification of the previously
described plaque assay, termed “viability assay”. Aliquots of 100 μL of
serially diluted bacteria/K1F-GFP phage extractions taken directly
from corresponding wells of the 96-well plate in the plate reader with
final volumes varied according to time points were spotted and spread
over a 1.5% agar LBA plate. After an overnight (24 h) incubation of
the plates at 37 °C, the number of E. coli colonies were counted to
determine the CFU·mL−1, accounting for sample dilutions. A
FLUOstar Omega microplate reader was used and data was obtained
from the MARS data analysis software. Each assay was carried out in
triplicate, using technical duplicates for each biological repeat (n = 6).
■ RESULTS AND DISCUSSION
Our initial hypothesis was that addition of ice recrystallization
inhibiting (IRI) polymers may mitigate cold-induced damage
to the phage, in particular by reducing the stress during the
thawing stage. The IRI-active polymer PVA (poly(vinyl
alcohol)) has shown benefit for protein storage57 (by reducing
aggregation), as well as bacteria,62 hence was chosen due to its
ease of use and commercial availability. To ensure PVA
retained IRI activity in the buffer used (SM-II) for handling
the phage, the “splat” assay was used to evaluate ice
growth.59,63 In this assay, small ice crystals were nucleated
and then allowed to grow at a subzero temperature (−8 °C)
and their mean grain size (MGS) is reported relative to the
buffer/media alone. This test is crucial, as solvent conditions
can enhance/reduce the IRI activity64 and saline is essential to
avoid false positives.59 Figure 1 shows the structures of the
polymers tested (PVA and PEG), for example, ice crystal
wafers and the MGS activity. As expected, PVA retained its IRI
activity inhibiting all growth at 1 mg·mL−1 but was slightly less
active than what is seen in standard-phosphate-buffered saline
(PBS) buffer, attributable to the additional solution
components. PEG shows no significant IRI activity in the
concentration range tested (noting that IRI is a continuum not
on/off property and very high concentrations of any polymer
will slow growth63). With this to hand, the polymers could be
used for phage testing, as shown below.
K1F was chosen as a model phage to check different
synthetic cryoprotectants. To evaluate phage recovery, the
plaque-forming units of infectious phage particles were
quantified after the thaw. This was achieved by inoculating
the E. coli host, EV36,65 and measuring the phage titer by the
number of plaques formed, following a standard bacterial
infection procedure called a plaque assay (see the Experimental
Section). The EV36 strain of E. coli is a K12/K1 hybrid,
meaning that it is a nonpathogenic lab strain that expresses the
Figure 1. Ice recrystallization inhibition activity of polymers in SM-II
buffer. (A) Example micrographs of ice wafers after 30 min annealing
at −8 °C. PEG (4000 g·mol−1), 10 mg·mL−1, and PVA (10 000 g·
mol−1), 1 mg·mL−1. Scale bars = 100 μM. (B) IRI activity as a
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K1 capsule.66 The K1 capsule is associated with pathogenic-
ity.66 Thus, this strain is used as a model for pathogenic E. coli
but without the hazards associated with working with a strain
expressing other pathogenic genes. K1F is a T7-like phage but
has an endosialidase gene in the position of the usual T7 tail
fiber gene.67 This means that, unlike T7, K1F has the ability to
break down the K1 capsule and making it of interest as a
clinical treatment.68 To evaluate cryopreservation conditions,
the K1F-GFP phage (∼1 × 106 PFU·mL−1) (plaque-forming
units) was mixed with the cryopreservation solutions, frozen to
either −20 or −80 °C (representing a standard and ultra-low-
temperature freezer) for 13 days. After the thaw, the diluted
lytic phage was grown on a lawn of its host bacteria, and by
counting zones of clearance, the PFUs (plaque-forming units)
were quantified (Figure 2A). The positive control for this study
was 50 wt % glycerol (a commonly used reagent for phage
cryopreservation).69 Recovery data is shown in Figure 2B/C.
The total phage recovered shown by the positive control
cryoprotected sample is visibly higher at −20 °C compared to
−80 °C, which is partly due to the fact that 50 wt % glycerol
does not freeze in a standard freezer, resulting in a chilled state
of the aliquot for the 13 days period, avoiding any freeze−thaw
damage. After storage at −20 °C, it was clear that all solutions
containing PEG showed higher recovery, up to 100-fold, than
SM-II buffer alone (negative control), as shown in Figure 2B.
Our original hypothesis was that PVA (as an IRI-active
component) would enhance post-thaw yields, but in each case,
there was no change in the phage titer compared to the
formulations with no PVA. PVA alone (Supporting Informa-
tion, Figure S1) also showed no benefit. Changing to −80 °C
cryopreservation, all polymer formulations matched the
performance of 50 wt % glycerol (Figure 2B). This was a
surprising level of recovery, considering the polymers were
used at a 50-fold lower concentration than glycerol. As seen
after storage at −20 °C, there was no impact of the PVA on
phage recovery after storage at −80 °C when compared to the
negative control (Supporting Information, Figure S1).
These initial results confirmed that a macromolecular
cryoprotectant for phage cryopreservation is not only feasible
but very potent. It also showed that (under the present
conditions, noting that volume and thawing rates can all play a
role) ice recrystallization is not a major stress factor for phage
cryopreservation when performed in the presence of PEG. For
solvent-free bacteria cryopreservation using IRI-active materi-
als, it has been observed that an additional hydrophilic polymer
(such as PEG) was essential for the IRI-active polymer to
provide benefit and hence a similar effect may be occurring
here. PEG is also known to stabilize proteins during freeze−
thawing,70,71 via a proposed preferential steric exclusion of
PEG from the surface of proteins, alleviating any potential
deactivation, in addition to their hydration.72−74 Previous
studies69 have shown that concentrations of PEG at both 10
and 45% w/v led to similar mean survival times of rabies virus
compared to similar concentrations of other cryoprotectants,
sucrose, DMSO, and glycerol, after 30-day storage at −20 °C.
A discussion on the potential role of osmotic stress is included
later in this manuscript.
The above data was from a single freeze−thaw cycle.
Therefore, as a more robust challenge, the phage was exposed
to a series of 5, 10, or 15 freeze (−80 °C)/thaw (20 °C) cycles.
Repeated freeze−thaw cycles may cause extended freeze−thaw
damage, through deliberate or accidental warming of samples.
PVA was included again, to ensure that any excess ice
recrystallization damage could be probed (Figure 3). In each
case, nearly full recovery of the phage, compared to the day 0
control, was achieved with just 10 mg·mL−1 PEG. The PVA
again showed no significant impact (neither positive nor
negative). This data showed that the polymeric cryoprotectant
strategy is suitable for repeated use, for e.g., a research
environment, where stocks may be thawed, sampled, and
refrozen, with no detriment to the sample function and
integrity.
The above data shows that the addition of polymers as
cryoprotectants allows increased post-thaw yield of the K1F-
GFP phage. One intended application of phage is a therapy to
kill pathogenic bacteria, as an alternative to traditional
Figure 2. K1F-GFP phage cryopreservation and recovery with a single
freeze (−80 °C)/thaw (20 °C) cycle. (A) Schematic of freeze/thaw
and quantification of phage recovery. (B) Phage titer after
cryopreservation at −20 °C. (C) Phage titer after cryopreservation
at −80 °C. Each sample was 500 μL. Errors bars are standard
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antibiotic treatments, or as a phage-antibiotic synergy (PAS)
aiming to reduce the dose of antibiotics and the development
of antimicrobial resistance (AMR).75 The maintenance of
efficacy and the lytic ability of our phage after cryopreservation
was checked by measuring changes in optical density (OD600)
in a growth curve over a 24 h period. In this assay, the phage
was cryopreserved with 10 mg·mL−1 PEG, thawed, and then
added to a culture of E. coli, and the change in turbidity was
measured by absorbance at 600 nm. In media alone, the E. coli
reached a plateau (stationary phase) within 12 h and a positive
control of 1% v/v Chemgene HLD4L disinfectant (containing
didecyldimethylammonium chloride) arrested all growth in the
same time period. Addition of the noncryopreserved phage
successfully prevented bacterial growth up to 8 h, after which
time growth recovered (as the dose did not irradicate all E. coli
and there was resistant strain outgrowth). The phage
cryopreserved with both PEG or PEG/PVA showed similar
performance in this assay. Bacteria were also quantified at the 7
h time point, via cell plating and quantifying the number of
colony-forming units (Figure 4B). Additional plaque-forming
units (PFU) and colony-forming units (CFU) measured at the
7 h, 10 h, and 24 h time points are included in the
Supplementary Information (Figures S2 and S3). The
disinfectant (positive) control showed no live bacteria (limit
of detection = 1 log CFU·mL −1). After treatment with the
cryopreserved phage, statistically similar bacterial titers were
measured when compared with treatment with the fresh phage
samples. This data shows that the cryopreserved phage, using
biocompatible polymers, could potentially be used as frozen
phage stocks ready to be deployed, by simple thawing, for use
in emerging therapeutic applications, with their performance
matching that of the fresh phage.
While the genetic and molecular approaches to under-
standing the growth, metabolism, adaptability, and physiology
of bacteria (such as our E. coli EV36 host) have focused on
studying planktonic cells in batch cultures, many bacteria (E.
coli included) live primarily in immobile communities, referred
to as biofilms.76 Besides being the major cause for recurrent
urinary tract infections (UTI), E. coli biofilms are one of the
pathogens commonly responsible for medical device-related
infectivity.77 Therefore, as a second method of comparing the
performance of fresh and cryopreserved K1F-GFP bacter-
iophages, E. coli biofilm eradication was investigated
(Supporting Information, Figure S4). The cryopreserved
phage showed similar effects as the fresh phage (∼ 10-fold
reduction in bacterial CFU) after a single application.
However, compared to the positive control (1% v/v
Chemgene) despite the slight reduction in the E. coli CFU,
the phages (both cryopreserved as fresh) were inefficient at
eradicating the mature biofilm (72 h grown). As 24 and 48 h
grown biofilms were not investigated, the thickness of the
biofilm cannot be ruled out as a contributing factor to phage
eradication inefficiency.
The above data was using a K1F-GFP phage, so it was
important to evaluate if other phages responded in a similar
manner. The T4 bacteriophage was chosen due to being a well-
studied model phage for E. coli.78 Like K1F, T4 encodes its
own replication proteins, bypassing the host replication
machinery.79 T4 is also clinically relevant, with evidence of
low immunogenicity in oral application and with potential uses
for oral vaccine development.80 Due to its clinical relevance
and the breadth of information already available on T4, it is an
ideal candidate to evaluate our cryoprotectants. Identical
freeze−thaw conditions were applied, as used previously, and
the results of the cryopreservation at both −20 and −80 °C are
shown in Figure 5. It was observed that the T4 phage was more
Figure 3. Post-thaw recovery of the K1F-GFP phage following
variable freeze (−80 °C)/thaw (20 °C) cycles. Control is PVA [1 mg·
mL−1] after 15 cycles. Error bars represent SD from three biological
and two technical replicates. Figure 4. E. coli growth inhibition by the K1F-GPF phage. (A)
Growth curves of E. coli EV36 upon addition of the phage or controls.
Phages were added during the log phase (4 h) to a final concentration
of 1 × 106 PFU·mL−1. PEG and PEG/PVA refer to the cryopreserved
phage using those additives. The K1F-GFP phage was freeze (−80
°C)−thawed (20 °C); (B) E. coli EV36 viability at 7 h, determined by
extraction of the sample from the growth experiment (part A) and
plating and counting colony-forming units. [Disinfectant] = 1% v/v
Chemgene; [PEG] = 10 mg·mL−1; [PEG/PVA] = 10 + 1 mg·mL−1.
Error represents SD from three biological and two technical replicates.
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susceptible to cold damage than the previously used K1F and
that 50% glycerol provided little protection at both freezing
temperatures. It should be noted that the EV36 strain is not
the ideal host for this T4 phage, as the K1 capsule blocks the
phage receptors. However, EV36 is a hybrid of K1/K12, so
infection with the T4 phage (which naturally targets K12) still
leads to plaque formation, which was visibly smaller in size
compared to K1F plaques, as EV36 is not the natural host for
T4. The same E. coli EV36 host was used here though, to allow
comparison in the present context. As seen for the K1F phage,
addition of the polymeric cryopreservation formulation in all
cases leads to a greater post-thaw phage titer of approximately
100-fold. This increase, if put in the context of therapy, would
mean that using this polymeric cryopreservation strategy would
deliver a 100-fold higher dosage compared to a glycerol frozen
solution or allow more treatments from a single stock. The
utility across two distinct classes of phages also suggests that
this approach could be used to generate bespoke phage
cocktails, although this will be the subject of a future
investigation.
As further controls, we tested poly(vinylpyrrolidone) and
hydroxyethyl starch for phage cryopreservation, as both of
these polymers are widely used in formulations or for
cryopreservation.81,82 In the initial screening (Supporting
information, Figure S5), both PVP and HES increased post-
thaw titers of the K1F phage, to an extent less than PEG.
However, based on our preliminary results, we cannot
conclude which one is more efficient and a full comparison
of the materials would be required. To the best of our
knowledge, there are no studies on the use of polymer-only
solutions to preserve the bacteriophage, but our data suggests
that hydrophilic polymers can be used as a simplistic
cryoprotectant solution and a detailed structure−function
study of this will be undertaken in the future, as well as the
response of different phage strains. There is evidence that
osmotic stress plays a key role in phage storage. As shown by
Duyvejonck,83 several myoviridae and podoviridae (groups
encompassing T4 and T7 phages, respectively) were resistant
to storage conditions in Dulbecco’s phosphate-buffered saline
(DPBS) (with and without Ca2+/Mg2+) with maintained
infectivity up to 554 and 243 days, respectively, at 4 °C.
Interestingly, when the T4B phage was rapidly transferred from
a concentrated to a dilute solution, retained phage activity
depended on the initial salt concentration of the solution in
which it was suspended.84 Phage inactivation observed during
rapid dilution did not occur during slow dilutions. A rapid
change in osmotic pressure caused by the change in salt
concentration may cause the phage DNA to extrude from the
tail or their heads to break, as observed by Lark and Adams.85
In our study, the addition of the PEG may affect the water
diffusion rates in the unfrozen channels formed during
freezing, due to increased viscosity, which has been seen for
glycerol (positive control used here)86 and mitigated the
osmotic stress encountered. High concentrations of PEG (10−
45 wt %) have been shown to protect against rabies virus
during cryopreservation.69
■ CONCLUSIONS
Here, we report that the bacteriophage can be successfully
cryopreserved across a range of temperatures by the addition
of poly(ethylene glycol), PEG, and other hydrophilic polymers,
as an alternative to some of the currently used buffers, such as
those containing glycerol. K1F and T4 bacteriophages were
used to evaluate performance. It was found that just 10 mg·
mL−1 (∼1 wt %) of PEG allowed plaque-forming unit recovery
matching that from a positive control of 50 wt % glycerol at
−80 °C but slightly underperforming at −20 °C. It should be
noted that the glycerol solutions do not actually freeze at −20
°C, making direct comparisons challenging but showing that
conventional laboratory freezers can be used to freeze the
phage using our polymeric system. Using the polymer
formulation, near 100% phage recovery was achieved
(represented as plaque-forming units), even after 15 freeze/
thaw cycles, demonstrating that this provides robust
protection, which can be applied to larger sample sizes in a
practical setting. The role of ice recrystallization was probed
using the potent ice recrystallization inhibitor poly(vinyl
alcohol), PVA, which has been found to be useful in other
cryopreservation scenarios. In all cases, addition of PVA
showed no significant benefit, suggesting that ice growth
during thawing and hence irreversible aggregation are not a
major mechanism of damage for the phage. The polymers may
be reducing osmotic stress, by impacting diffusion in unfrozen
channels, but more research is needed to elucidate a
mechanism. In E. coli kill studies, the cryopreserved phages
Figure 5. T4 phage titers after one freeze−thaw cycle at −20 °C (A)
and −80 °C (B) freezing for 13 days. Day 0 = titer on the day of
freezing; negative control = the phage without the additive at −20 and
−80 °C; positive control = 50 wt %. glycerol; red = phage and
additives. Cryopreserved samples were 500 μL. Error represents
standard deviation from three biological and two technical replicates.
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were found to match the performance of fresh phages,
demonstrating that this approach may allow for frozen pure
or cocktails of the phage, intended for therapy, to be stored as
cryopreserved stocks. As PEG is biocompatible, has low
immunogenicity, and is edible, it would not need to be
removed after the thaw. Preliminary data also showed that
other hydrophilic polymers can provide this protection and
that the protective capacity is not unique to PEG and that
protecting the phage from cold damage (compared to other
biologics) may be relatively straightforward. The extent and
magnitude of protection between different macromolecular




The Supporting Information is available free of charge at
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